Page last updated: 2024-12-10

leukotriene a4

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Leukotriene A4: (2S-(2 alpha,3 beta(1E,3E,5Z,8Z)))-3-(1,3,5,8-Tetradecatetraenyl)oxiranebutanoic acid. An unstable allylic epoxide, formed from the immediate precursor 5-HPETE via the stereospecific removal of a proton at C-10 and dehydration. Its biological actions are determined primarily by its metabolites, i.e., LEUKOTRIENE B4 and cysteinyl-leukotrienes. Alternatively, leukotriene A4 is converted into LEUKOTRIENE C4 by glutathione-S-transferase or into 5,6-di-HETE by the epoxide-hydrolase. (From Dictionary of Prostaglandins and Related Compounds, 1990) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

leukotriene A4 : A leukotriene that is the (5S,6S)-epoxy derivative of (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5280383
CHEMBL ID69439
CHEBI ID15651
SCHEMBL ID247614
MeSH IDM0026633

Synonyms (36)

Synonym
5s,6s-leukotriene a4
oxiranebutanoic acid, 3-(1,3,5,8-tetradecatetraenyl)-, (2s-(2alpha,3beta(1e,3z,5z,8z)))-
(5s,6s,7e,9e,11z,14z)-5,6-epoxyicosa-7,9,11,14-tetraenoic acid
CHEBI:15651 ,
5(s)-5,6-oxido-7,9-trans-11,14-cis-eicosatetraenoic acid
5s,6s-epoxy-7e,9e,11z,14z-eicosatetraenoic acid
chembl69439 ,
4-[(2s,3s)-3-[(1e,3e,5z,8z)-tetradeca-1,3,5,8-tetraen-1-yl]oxiran-2-yl]butanoic acid
4-{(2s,3s)-3-[(1e,3e,5z,8z)-tetradeca-1,3,5,8-tetraen-1-yl]oxiran-2-yl}butanoic acid
bdbm24200
LMFA03020023
leukotriene a4
(7e,9e,11z,14z)-(5s,6s)-5,6-epoxyicosa-7,9,11,14-tetraenoate
(5s,6s,7e,9e,11z,14z)-5,6-epoxyicosa-7,9,11,14-tetraenoate
(7e,9e,11z,14z)-(5s,6s)-5,6-epoxyeicosa-7,9,11,14-tetraenoic acid
C00909
(7e,9e,11z,14z)-(5s,6s)-5,6-epoxyeicosa-7,9,11,14-tetraenoate
lta4
72059-45-1
leukotriene a
4-[3-(3-cyclohepta-2,5-dien-1-ylideneprop-1-enyl)oxiran-2-yl]butanal
unii-7y7mpz6563
7y7mpz6563 ,
gtpl5214
(2s,3s)-3-(1e,3e,5z,8z)-1,3,5,8-tetradecatetraenyloxiranebutanoic acid
leukotriene a4 [mi]
2-oxiranebutanoic acid, 3-(1e,3e,5z,8z)-1,3,5,8-tetradecatetraen-1-yl-, (2s,3s)-
SCHEMBL247614
UFPQIRYSPUYQHK-WAQVJNLQSA-N
(7e,9e,11z,14z)-(5s,6s)-5,6-epoxyicosa-7,9,11,14-tetrenoioc acid
5s,6s-epoxy-7e,9e,11z,14z-eicosatetraenoate
(7e,9e,11z,14z)-(5s,6s)-5,6-epoxyicosa- 7,9,11,14-tetraenoate
(7e,9e,11z,14z)-(5s,6s)-5,6-epoxyicosa- 7,9,11,14-tetraenoic acid
5s-5,6-oxido-7,9-trans-11,14-cis-eicosatetraenoic acid
DTXSID40903945
Q3024044

Research Excerpts

Overview

Leukotriene A4 hydrolase is a bifunctional zinc metalloenzyme. It catalyzes the final step in the biosynthesis of the proinflammatory mediator leukOTriene B4.

ExcerptReferenceRelevance
"Leukotriene A4 hydrolase is a zinc-containing enzyme which exhibits both epoxide hydrolase and aminopeptidase activities. "( Development of selective tight-binding inhibitors of leukotriene A4 hydrolase.
Haeggström, JZ; Munoz, B; Samuelsson, B; Wetterholm, A; Wong, CH; Yuan, W, 1993
)
1.98
"Leukotriene A4 hydrolase is a bifunctional zinc metalloenzyme that catalyzes the final step in the biosynthesis of the proinflammatory mediator leukotriene B4. "( Mutation of tyrosine 383 in leukotriene A4 hydrolase allows conversion of leukotriene A4 into 5S,6S-dihydroxy-7,9-trans-11,14-cis-eicosatetraenoic acid. Implications for the epoxide hydrolase mechanism.
Andberg, MB; Haeggström, JZ; Hamberg, M, 1997
)
2.03
"Leukotriene A4 hydrolase is a cytosolic metalloenzyme of the arachidonic acid biosynthetic pathway responsible for leukotriene A4 conversion into leukotriene B4. "( Evidence for a leukotriene A4 hydrolase in Xenopus laevis skin exudate.
Barre, N; Cadel, S; Clamagirand, C; Cohen, P, 1998
)
2.1

Effects

ExcerptReferenceRelevance
"Rac-leukotriene A4 methyl ester has been synthesized from propargylic alcohol and 1-heptyne. "( [Synthesis of leukotriene A4 methyl ester via acetylene intermediates].
Belosludtsev, IuIu; Bobrova, NI; Evstigneeva, RP; Miagkova, GI; Pivnitskiĭ, KK, 1986
)
1.19

Treatment

ExcerptReferenceRelevance
"Treatment of leukotriene A4 (LTA4) methyl ester with sodium hydroxide in aqueous methanol at 4 degrees C afforded LTA4, the presence of which was inferred from the UV spectrum of the compound, its rate of reaction with water, and the identity of the hydration products obtained. "( Leukotriene A4: preparation and enzymatic conversion in a cell-free system to leukotriene B4.
Anderson, MS; DeSousa, DM; Kuehl, FA; Maycock, AL, 1982
)
2.08

Dosage Studied

ExcerptRelevanceReference
" A dose-response curve was constructed and revealed that the above changes became evident when the platelet number exceeded 10(7)."( Transcellular lipoxygenase metabolism between monocytes and platelets.
Bigby, TD; Meslier, N, 1989
)
0.28
" Cumulative administrations of leukotrienes desensitized the lung strip, whereas non-cumulative dose-response relationships for the leukotrienes and histamine were reasonably parallel."( Mechanisms of leukotriene-induced contractions of guinea pig airways: leukotriene C4 has a potent direct action whereas leukotriene B4 acts indirectly.
Dahlén, SE; Granström, E; Hammarström, S; Hedqvist, P; Lindgren, JA; Rådmark, O; Westlund, P, 1983
)
0.27
" However, the epithelial cell enzyme had a slower time course for product generation and demonstrated a different dose-response relationship to substrate when compared with the neutrophil."( Characterization of human airway epithelial cell leukotriene A4 hydrolase.
Baker, JR; Bigby, TD; Lee, DM; Minami, M; Ohishi, N; Shimizu, T, 1994
)
0.54
" Dose-response studies indicated that 5-HPETE was a potent (IC25 = 10(-8) M) inhibitor of Na+, K(+)-ATPase activity."( 5-HPETE is a potent inhibitor of neuronal Na+, K(+)-ATPase activity.
Foley, TD, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
leukotrieneAny icosanoid from that family of C20 polyunsaturated fatty acids and their derivatives generated by leukocytes from arachidonic acid, each member having four double bonds of which three are conjugated.
oxylipinAny member of the group of bioactive lipids made by oxidation of polyunsaturated fatty acids.
epoxy fatty acidA heterocyclic fatty acid containing an epoxide ring as part of its structure.
polyunsaturated fatty acidAny fatty acid containing more than one double bond. Acids in this group are reported to have cardioprotective effects; and levels are lowered in chronic fatigue syndrome.
long-chain fatty acidA fatty acid with a chain length ranging from C13 to C22.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (58)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
Arachidonic acid metabolism3682
Synthesis of Leukotrienes (LT) and Eoxins (EX)1329
Biosynthesis of specialized proresolving mediators (SPMs)13107
Synthesis of Lipoxins (LX)616
Arachidonic Acid Metabolism2966
Leukotriene C4 Synthesis Deficiency2966
Piroxicam Action Pathway2967
Acetylsalicylic Acid Action Pathway2967
Etodolac Action Pathway2967
Ketoprofen Action Pathway2967
Ibuprofen Action Pathway5076
Rofecoxib Action Pathway2967
Diclofenac Action Pathway2967
Sulindac Action Pathway2967
Celecoxib Action Pathway3573
Ketorolac Action Pathway2967
Suprofen Action Pathway2967
Bromfenac Action Pathway2967
Indomethacin Action Pathway3067
Mefenamic Acid Action Pathway2967
Oxaprozin Action Pathway2967
Nabumetone Action Pathway2967
Naproxen Action Pathway2967
Diflunisal Action Pathway2967
Meloxicam Action Pathway2967
Valdecoxib Action Pathway2967
Antipyrine Action Pathway2967
Antrafenine Action Pathway2967
Carprofen Action Pathway2967
Etoricoxib Action Pathway2967
Fenoprofen Action Pathway2967
Flurbiprofen Action Pathway2967
Magnesium Salicylate Action Pathway2967
Lumiracoxib Action Pathway2967
Lornoxicam Action Pathway2967
Phenylbutazone Action Pathway2967
Nepafenac Action Pathway2967
Trisalicylate-Choline Action Pathway2967
Tolmetin Action Pathway2967
Tiaprofenic Acid Action Pathway2967
Tenoxicam Action Pathway2967
Salsalate Action Pathway2967
Salicylate-Sodium Action Pathway2967
Salicylic Acid Action Pathway2967
Acetaminophen Action Pathway2967
Prostaglandin and Leukotriene metabolism ( Prostaglandin and Leukotriene metabolism )2223
Metabolism of alpha-linolenic acid615
Eicosanoid metabolism via lipooxygenases (LOX)040
Prostaglandin and leukotriene metabolism in senescence619
Leukotriene metabolic pathway219
Arachidonic acid (AA, ARA) oxylipin metabolism076
Folic acid network070
Eicosanoid metabolism via lipoxygenases (LOX)040
Selenium micronutrient network095
Eicosanoid synthesis026
Arachidonic acid metabolism via LOX (Lipooxygenase) pathway033

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)IC50 (µMol)2.00000.00011.68479.3200AID6952
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Leukotriene A-4 hydrolaseHomo sapiens (human)Km7.60007.60007.60007.6000AID99753
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (37)

Processvia Protein(s)Taxonomy
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
proteolysisLeukotriene A-4 hydrolaseHomo sapiens (human)
lipid metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to zinc ionLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene biosynthetic processLeukotriene A-4 hydrolaseHomo sapiens (human)
protein metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
peptide catabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to peptide hormoneLeukotriene A-4 hydrolaseHomo sapiens (human)
type I pneumocyte differentiationLeukotriene A-4 hydrolaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
RNA bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
epoxide hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene-A4 hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
protein bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
peptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
zinc ion bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
tripeptide aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
metalloaminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular regionLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleoplasmLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
extracellular exosomeLeukotriene A-4 hydrolaseHomo sapiens (human)
tertiary granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
ficolin-1-rich granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleusLeukotriene A-4 hydrolaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID6952Inhibitory activity against 5-lipoxygenase1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Synthesis and 5-lipoxygenase inhibitory activities of eicosanoid compounds.
AID99759Kinetic parameter kcat against LTA4 hydrolase purified from human leukocytes1993Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2
Development of selective tight-binding inhibitors of leukotriene A4 hydrolase.
AID234198Ratio kcat /Km (1/M 1/s)1993Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2
Development of selective tight-binding inhibitors of leukotriene A4 hydrolase.
AID6959Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Synthesis and 5-lipoxygenase inhibitory activities of eicosanoid compounds.
AID99755Kinetic parameter Vmax against LTA4 hydrolase purified from human leukocytes was determined1993Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2
Development of selective tight-binding inhibitors of leukotriene A4 hydrolase.
AID99753Kinetic parameter (Km) for hydrolysis of LTA4 hydrolase purified from human leukocytes1993Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2
Development of selective tight-binding inhibitors of leukotriene A4 hydrolase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (366)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990163 (44.54)18.7374
1990's116 (31.69)18.2507
2000's54 (14.75)29.6817
2010's27 (7.38)24.3611
2020's6 (1.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.88 (24.57)
Research Supply Index5.94 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index44.95 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.53%)5.53%
Reviews43 (11.44%)6.00%
Case Studies2 (0.53%)4.05%
Observational0 (0.00%)0.25%
Other329 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]